European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET? (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Na?ve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis

發(fā)布時(shí)間： 2020-03-09 閱讀：1087次

分享

March 6, 2020-- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission has approved a change to the marketing authorization for MAVIRET? (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-na?ve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection.

"A shorter treatment duration means that more patients with HCV can be treated with an 8-week course of MAVIRET in the absence of initial tests to determine their genotype or degree of fibrosis or cirrhosis," said Janet Hammond M.D., Ph.D., vice president, general medicine and virology therapeutic area, AbbVie. "The ability to streamline pre-treatment assessment for people with HCV represents a paradigm shift in the way the disease is treated, potentially accelerating the care cascade and allowing us to make greater strides towards achieving the World Health Organization's goal of eliminating HCV by 2030."

"Despite hepatitis C now being curable, there are millions of people in Europe who are chronically infected with the virus. Many of these patients have never received treatment, often because they have been unable to navigate the practical and clinical complexities of the treatment journey," said Stefan Zeuzem, M.D., chief of the department of medicine at the J.W. Goethe University Hospital in Frankfurt, Germany. "A shorter-duration therapeutic option and simplified pre-treatment approach can eliminate the need for extra tests and help significantly more people overcome their very real treatment barriers."

In the World Health Organization (WHO) European Region, 14 million people are estimated to be chronically infected with the hepatitis C virus and many of them are unaware that they are infected.3 Each year 112,500 people die from hepatitis C-related liver disease.